System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Giovanni Monteleone is an expert in Gastroenterology at Policlinico Tor Vergata (Italy). As of October 2026, ScienceLeadR ranks Giovanni Monteleone in the top 1% of experts worldwide for Colitis, Gastroenteritis and Inflammatory Bowel Diseases. Giovanni Monteleone has authored 741 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 3 of them ongoing. SLR score: 2,928 (community average: 125). How the SLR is computed.

LeadR Profile

Giovanni Monteleone Policlinico Tor Vergata Italy
2 928 ScienceLeadR Reputation 2928

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Medical Imaging - Biochemistry - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Sapienza University of Rome

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 741

Citations

Citations: 25 107 1st author: 70 Last author: 342 Unique author: 0

Main journals

Dig Liver Dis 172
Gastroenterology 74
J Crohns Colitis 29
Cancers (Basel) 19
Inflamm Bowel Dis 19

Best Journals

N Engl J Med 3
Gastroenterology 1
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Corrigendum to "Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology" [Digestive and Liver Disease 58 (2026) 1051-1060].
PMID 42669572 — liver diseases, rheumatology, gastroenterology, liver, dermatology		Dig Liver Dis20260
Individual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database.
PMID 42663308 — quality of life, mortality, stress, physiological, signs and symptoms, covid-19, stress disorders, traumatic, research, infections		Health Soc Care Deliv Res20261
SMAD7-Associated Glycolytic Regulation Promotes Lactate-Dependent Macrophage Phenotype Modulation in Colorectal Cancer.
PMID 42650029 — cells, macrophages, neoplasms, phenotype, colorectal neoplasms, tumor microenvironment		Cancers (Basel)20260
BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype.
PMID 42635600 — cytokines, cells, tumor necrosis factor-alpha, polymerase chain reaction, phenotype, neutrophils, inflammatory bowel diseases, fibroblasts, tissues, colitis, ulcerative		J Crohns Colitis20260
Acquired Loss of IL-10 Function in Inflammatory Bowel Disease.
PMID 42551568 — inflammatory bowel diseases, interleukin-10		Gastroenterology20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 5
Phase 3 4
Phase 4 2

By status:

Completed 6
Active not recruiting 2
Recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 11

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 2
multicentric5to9 1
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An Adaptive Dose Ranging Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00 — colitis, therapeutics, colitis, ulcerative		Phase 2Active not recruiting2025
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn s Disease
2024-513009-30-00 — crohn disease, therapeutics		Phase 2Recruiting2024
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943 — interleukin-23, anti-inflammatory agents, colitis, digestive system diseases, colonic diseases, interleukin-23 subunit p19, inflammatory bowel diseases, intestinal diseases, therapeutics, digestive system, gastrointestinal diseases, ligands, colitis, ulcerative		Phase 2Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS